Navigation Links
InterMune Reports First Quarter 2009 Financial Results and Business Highlights
Date:4/30/2009

after the call.

To access the webcast, please log on to the company's website at www.intermune.com at least 15 minutes prior to the start of the call to ensure adequate time for any software downloads that may be required.

The teleconference replay will be available approximately three hours after the call. The teleconference replay will be available for 10 business days following the call and can be accessed by dialing 800-642-1687 (U.S.) or 706-645-9291 (international), and entering the conference ID# 95970767. The webcast will remain available on the company's website until the next earnings call.

About InterMune

InterMune is a biotechnology company focused on the research, development and commercialization of innovative therapies in pulmonology and hepatology. InterMune has an R&D portfolio addressing idiopathic pulmonary fibrosis (IPF) and hepatitis C virus (HCV) infections. The pulmonology portfolio includes pirfenidone for which a Phase 3 program in patients with IPF (CAPACITY) has been completed and the compound is currently in the pre-registration stage. The company also has a research program focused on a pirfenidone analog named ITMN-520. The hepatology portfolio includes the HCV protease inhibitor compound ITMN-191 (referred to as R7227 at Roche) expected to enter Phase 2b in the summer of 2009 and a second-generation HCV protease inhibitor research program. For additional information about InterMune and its R&D pipeline, please visit www.intermune.com.

Forward-Looking Statements

This news release contains forward-looking statements within the meaning of section 21E of the Securities Exchange Act of 1934, as amended, that reflect InterMune's judgment and involve risks and uncertainties as of the date of this release, including without lim
'/>"/>

SOURCE InterMune, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13

Related biology technology :

1. InterMune to Release First Quarter Financial Results on April 30
2. InterMune and Pharmasset to Discuss INFORM-1 Results From EASL Conference, April 25
3. InterMune to Present at Canaccord Adams Hepatitis C Conference
4. InterMune to Present at Citis 4th Annual Biotech Day
5. InterMune to Present Abstracts on HCV Protease Inhibitor ITMN-191 and HCV Development Program at the EASL Meeting
6. InterMune Reports Fourth Quarter and Full Year 2008 Financial Results and Business Highlights
7. InterMune to Release Fourth Quarter, Full Year 2008 Financial Results on February 26
8. InterMune Announces Issuance of U.S. Patent for ITMN-191
9. InterMune Announces Pricing of Public Offering of 3,500,000 Shares of Common Stock
10. InterMune Reports Results of Two Phase 3 CAPACITY Studies of Pirfenidone in IPF
11. InterMune to Present at J.P. Morgan Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/21/2014)... 21, 2014  BioSpecifics Technologies Corp. (NASDAQ: ... in class collagenase-based products marketed as XIAFLEX ® ... U.S. and XIAPEX ® in the EU, ... randomized, double-blind Phase 2a study of CCH for ... panniculopathy. The results showed that all three doses ...
(Date:8/21/2014)... observed tiny quantum vortices in cold droplets of liquid ... that the exotic vortices arrange themselves as densely ... time that the quantum vortices, which have already been ... superfluid helium, have been detected in nanodroplets. "The experiment ... the University of Southern California, one of the experiment,s ...
(Date:8/21/2014)... 21, 2014 His Majesty Willem-Alexander, King ... The Court of His Majesty Willem-Alexander, King of the ... Grand Opening of POET-DSM Advanced Biofuels’ Project LIBERTY cellulosic ... , The King will take part in the Grand ... for 11 a.m.-12:20 p.m. and tour the plant. POET-DSM ...
(Date:8/21/2014)... , Aug. 21, 2014  Decision Resources Group ... Brazil and Mexico ... of several newly approved agents, the anticipated label ... and the launch of emerging biologics will substantially ... particular, the emerging IL-5 inhibitors will introduce a ...
Breaking Biology Technology:BioSpecifics Technologies Corp. Announces Positive Data from Phase 2a Study of CCH for Treatment of Cellulite 2BioSpecifics Technologies Corp. Announces Positive Data from Phase 2a Study of CCH for Treatment of Cellulite 3BioSpecifics Technologies Corp. Announces Positive Data from Phase 2a Study of CCH for Treatment of Cellulite 4BioSpecifics Technologies Corp. Announces Positive Data from Phase 2a Study of CCH for Treatment of Cellulite 5Scientists observe quantum vortices in cold helium droplets 2His Majesty Willem-Alexander, King of the Netherlands, to Attend Project LIBERTY opening 2His Majesty Willem-Alexander, King of the Netherlands, to Attend Project LIBERTY opening 3Asthma Agents Currently Face a Suboptimal Coverage Environment in Brazil and Mexico, and as the Treatment Armamentarium Expands, Competitiveness Will Further Intensify 2Asthma Agents Currently Face a Suboptimal Coverage Environment in Brazil and Mexico, and as the Treatment Armamentarium Expands, Competitiveness Will Further Intensify 3
... , , ... July 14 Accera, Inc., a biotechnology company delivering ... further evidence for genetic interactions impacting the efficacy of ... New data from the company,s previously completed double-blind, placebo-controlled ...
... ... ... July 14, 2009 -- Quantros, a leading provider of safety and quality software and ... Hospital and USC Kenneth Norris, Jr. Cancer Hospital at the University of Southern California. ...
... ... developed by Dr. Charles Stewart at DualAlign LLC is breaking new ground in medical ... and stitch images even if the originals were taken from different cameras, of varying ... , ...
Cached Biology Technology:Evidence for a New Genetic Link to Therapeutic Efficacy for Alzheimer's Disease 2Evidence for a New Genetic Link to Therapeutic Efficacy for Alzheimer's Disease 3Evidence for a New Genetic Link to Therapeutic Efficacy for Alzheimer's Disease 4USC Hospitals Extend Relationship With Quantros to Manage Compliance and Risk 2USC Hospitals Extend Relationship With Quantros to Manage Compliance and Risk 3Powerful Image Registration and Recognition Software Unveiled for Medical, Satellite, and Defense Imaging Industries 2Powerful Image Registration and Recognition Software Unveiled for Medical, Satellite, and Defense Imaging Industries 3
(Date:8/21/2014)... intake, health and quality of life of older adults ... the University of Waterloo receiving close to $1.5 million ... (CIHR). , Professor Heather Keller, of the Faculty ... research chair in nutrition and aging, will receive $979,000 ... in long-term care homes are poorly nourished. The project ...
(Date:8/21/2014)... In a finding that has implications for life ... elsewhere in the solar system, LSU Associate Professor of ... the National Science Foundation, or NSF, this week published ... a lake that lies 800 meters (2600 feet) beneath ... "viable microbial ecosystems.", Given that more than 400 subglacial ...
(Date:8/21/2014)... water window? It consists of radiations in the 3.3 ... the water in biological tissues. New theoretical findings show ... the water window. These could be the basis of ... the biological samples or to be used in high-precision ... mechanism needed to efficiently generate the harmonic radiationswhich are ...
Breaking Biology News(10 mins):Grants will fund landmark aging research at Waterloo 2800 meters beneath Antarctic ice sheet, subglacial lake holds viable microbial ecosystems 2800 meters beneath Antarctic ice sheet, subglacial lake holds viable microbial ecosystems 3800 meters beneath Antarctic ice sheet, subglacial lake holds viable microbial ecosystems 4Water window imaging opportunity 2
... in French . , Montreal, December 11, ... that prevents cancer. In the December 11 edition of the ... de Montral and the Universit de Sherbrooke explain how they ... cytokines, hormones that are culprits in cancer-prone chronic inflammation diseases ...
... Arno Motulsky, the senior editor of the 4th edition ... Human Genetics, was recently given the Victor A. McKusick ... contributions to the field of human genetics, was presented ... American Society of Human Genetics on 24 October 2009 ...
... ORFruit growers, profits have traditionally been limited by ... seasons can be short. Thanks to researchers and ... that offer growers the ability to produce fruit ... producers and consumers. Fresh examples are the new ...
Cached Biology News:Scientists identify natural anti-cancer defenses 2New management methods extend blackberry season 2
HybriWell seals securely to a microscope slide surface in seconds to enclose single or multiple specimens in a small reagent volume and eliminate evaporation....
... mm depth • Reusable, press-to-seal gasket and ... assembled and disassembled for hybridizing and imaging ... thickness with up to a 13 mm ... slide. Minimize specimen handling, eliminate evaporation and ...
... polystyrene formulation , High antibody-binding surface improves ... , Plates are certified for performance ... , Eight-well strips fit snugly in the plate ... even if turned upside down ...
12 breakable polypropylene strips of 8 wells each held in a rigid frame. Ideal for antibody assays....
Biology Products: